Manila, Philippines, 19 June 2010 - Focus Reports, the contract-publishing unit of Focus Communication, is currently preparing a special feature on the Filipino Pharmaceutical Industry. The special Philippines issue follows similar successful reports that Focus Reports has prepared in Asia Pacific such as Singapore, Thailand, Indonesia, China, Malaysia, India and Australia.
 
In a country with one of the world’s highest drug prices, changes brought about by the controversial Cheaper Medicine Act, passed in 2008, have tremendously impacted the Philippines pharmaceutical market, whereby 200 drugs have seen price reductions by up to 50% since August 2009.  In its commitment to improve healthcare and access to innovative medicine domestically, the watershed Act has opened exciting new directions and opportunities for the Filipino pharmaceutical industry, at home and abroad. 

Focus Reports will spotlight the post-Act industry as it focuses on developing its attractiveness and competitiveness in the region, especially in manufacturing and clinical trials. The report will highlight the growing momentum to pioneering research and development, and formulating breakthrough drugs, in a marked shift from the prevailing emphasis on manufacturing existing drugs.

The Philippines report will be introduced by the industry’s most authoritative personalities, such as Esperanza Cabral, Philippine Secretary of Health in the Department of Health (DOH); Jesli Lapus, secretary of the Department of Trade and Industry (DTI), Nazarita T. Tacandong, Director of the Food and Drug Administration (FDA); Jaime C. Montoya, Executive Director of the Philippine Council for Health Research and Development (PCHRD); Reiner Gloor, President & Executive Director of PHAP. In addition, the report will gather the views of the leading figures within the most prominent pharmaceutical companies in the Philippine Pharmaceutical Industry, such as: Clinton Campo, President and CEO of United Laboratories, Inc.; Marietta Guidote Guanzon, Chairman and President of ORO Enterprises; Abraham Pascual, Chairman and CEO of Pascual Laboratories; Emerenciana Lingad-Bautista, President Elin Pharmaceuticals; Mike Becker, President & CEO of Zuellig Pharma; Gerry E. Bacarro, Regional Director of Pfizer; Andrea Goedert, Managing Director of Boehringer Ingelheim; Roberto Taboada, President & Managing Director of Glaxosmithkline; Lourdes Magno, President of Eisai; amongst others.

In anticipation of the report’s publication this fall, select interviews will be regularly posted on pharma.focusreports.net  

SOURCE:  FOCUS COMMUNICATION

Focus Communication is a specialist B2B communications group uniquely positioned to promote business in government and strategic industries around the world. With offices in Beijing, Geneva, Moscow and Paris, the agency offers core competency in e-media & e-portal creation, event planning, PR, contract publishing, marketing solutions, media consultancy, business intelligence, and more. Industries in which Focus Communication has proven expertise include aerospace & air transport, defense, mining and metals, nuclear energy, oil & gas, pharmaceuticals, power generation, and renewable energy.